Spots Global Cancer Trial Database for Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Official Title: Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study

Study ID: NCT00004895

Conditions

Colorectal Cancer

Constipation, Impaction, and Bowel Obstruction

Extrahepatic Bile Duct Cancer

Gastric Cancer

Gastrointestinal Stromal Tumor

Nausea and Vomiting

Ovarian Cancer

Pancreatic Cancer

Peritoneal Cavity Cancer

Small Intestine Cancer

Interventions

octreotide acetate

Study Description

Brief Summary: RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably. PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.

Detailed Description: OBJECTIVES: * Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer. * Characterize the dose and tolerability of octreotide in this patient population. OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5. Patients who respond well to study may continue octreotide for palliative effects. PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.